 Vertex Pharmaceuticals Inc said it would seek regulatory approval later this year for an experimental cysticfibrosis drug that helped produce a statistically significant improvement in patients lung function compared with placebo in two latestage studies The studies tested Vertexs experimental drug lumacaftor in combination with its currently approved therapy ivacaftor known by the brand name Kalydeco in cysticfibrosis patients ages  and older with two copies of a rare genetic mutation 